News Conference News AHA 2025 POLY-HF: Polypill Pays Dividends in Patients With HFrEF Todd Neale November 14, 2025
News Conference News ESC 2025 Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR Michael O'Riordan August 31, 2025
News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Conference News European Congress on Obesity 2025 Higher CVD Risk in Children as Young as 10 Who Have Central Adiposity Michael O'Riordan May 16, 2025
News Conference News European Congress on Obesity 2025 App-Based Support Aids Weight Loss With Semaglutide, Studies Show Michael O'Riordan May 13, 2025
News Conference News THT 2023 High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF Todd Neale March 23, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT Michael O'Riordan November 05, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019
News Conference News AHA 2016 Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis Michael O'Riordan November 22, 2016